The Latest Cardiac and Vascular News
WINNIPEG, Dec. 17, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT® (tirofiban hydrochloride) injection versus Integrilin® (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial. SAVI-PCI was a randomized, multicenter, open-label study enrolling 535 patients at 13 sites in the United States, which compared […]
WINNIPEG, Dec. 12, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH), (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the FABOLUS-FASTER Phase 4 trial, a randomized, open-label, multi-center trial assessing different regimens of intravenous platelet inhibitors, notably tirofiban (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the […]
WINNIPEG, Nov. 26, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019. Quarter Ended September 30, 2019 Highlights: Recorded net revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $5.3 million during the quarter ended September 30, 2019 compared to $7.0 million for the quarter ended September 30, 2018; $35.7 […]
WINNIPEG, Oct. 15, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America (“HFSA”) conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator. The […]
WINNIPEG, Sept. 17, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the launch of the ReDSTM PRO (“ReDSTM PRO”) system, the next generation of lung fluid management technology for heart failure. The debut of the new system took place at the recent Heart Failure Society of America (“HFSA”) […]
WINNIPEG, Aug. 21, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Gland Pharma Ltd. (“Gland”) in the U.S. District Court for the District of New Jersey, which alleged infringement of Medicure’s U.S. Patent No. 6,770,660 (“the […]
WINNIPEG, Feb. 13, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that it has received notice from the purchaser of Medicure’s interests in Apicore of potential claims against funds held back in respect of representations and warranties under the Apicore sale agreement. The notice does not contain sufficiently detailed information […]
WINNIPEG, Jan. 28, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce it has entered into an agreement with Sensible Medical Innovations Inc. (“Sensible”) to become the exclusive marketing partner for the ReDS™ point of care system (“ReDS”) in the United States. ReDS is a non-invasive, FDA-cleared medical device […]
WINNIPEG, Aug. 13, 2018 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the United States Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial (“SNP”), a generic intravenous cardiovascular drug […]
WINNIPEG, April 24, 2018 /PRNewswire/ – Medicure Inc. (“Medicure”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the year ended December 31, 2017 after market close on Monday, April 30, 2018. Medicure will hold a conference call and webcast regarding the results on Tuesday, May 1, 2018at 7:30 AM Central Time (8:30 AM Eastern Time). Conference Call Info: Topic: […]
